Clinical trials
Sepsis trials in Greece
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 8 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Recruiting | 7 |
| Unknown status | 5 |
| Active, not recruiting | 2 |
| Terminated | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hellenic Institute for the Study of Sepsis | 15 |
| University of Athens | 7 |
| University of Thessaly | 3 |
| Aristotle University Of Thessaloniki | 2 |
| Inflammatix | 2 |
| Aisthesis Medical P.C. | 1 |
| AstraZeneca | 1 |
| Basilea Pharmaceutica | 1 |
| Charalambos .A. Gogos | 1 |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sepsis | 43 |
| Infections | 8 |
| Bacteremia | 4 |
| Community-Acquired Pneumonia | 4 |
| Disease | 4 |
| Intraabdominal Infections | 4 |
| Urinary Tract Infections | 4 |
| Pneumonia | 3 |
| Respiratory Tract Infections | 3 |
| Shock, Septic | 3 |
Trials
Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.